No Data
No Data
No Data
No Data
No Data
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after th
GlobeNewswire04:05
Crinetics(CRNX.US) Officer Sells US$639.26K in Common Stock
$Crinetics(CRNX.US)$ Officer Pizzuti Dana sold 14,375 shares of common stock on Apr 15, 2024 at an average price of $44.47 for a total value of $639.26K.Source: Announcement What is statement of chang
Futu NewsApr 18 05:18
Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing
Dana Pizzuti, Chief Medical and Development Officer, on April 15, 2024, sold 14,375 shares in Crinetics Pharmaceuticals (CRNX) for $639,256. Following the Form 4 filing with the SEC, Pizzuti has contr
MT NewswiresApr 18 04:41
Crinetics Pharmaceuticals Insiders Sold US$2.4m Of Shares Suggesting Hesitancy
In the last year, many Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) insiders sold a substantial stake in the company which may have sparked shareholders' attention.
Simply Wall StApr 17 18:34
Form 144 | Crinetics(CRNX.US) Officer Proposes to Sell 639.31K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 15, $Crinetics(CRNX.US)$ Officer DANA J PIZZUTI intends to sell 14,375 shares of its common stock on Apr 15, with a total market value of approximately $639.31K. DANA J P
Futu NewsApr 16 04:21
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified
GlobeNewswireApr 12 04:05
No Data
No Data